1. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
- Author
-
Yoshino, Takayuki, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Wainberg, Zev, Elez, Elena, Rodriguez, Javier, Fakih, Marwan, Ciardiello, Fortunato, Saxena, Kapil, Kobayashi, Kojiro, Bako, Emarjola, Okuda, Yasuyuki, Meinhardt, Gerold, Grothey, Axel, Siena, Salvatore, and DESTINY-CRC01 investigators
- Subjects
DESTINY-CRC01 investigators ,Humans ,Breast Neoplasms ,Colonic Neoplasms ,Rectal Neoplasms ,Camptothecin ,Receptor ,erbB-2 ,Immunoconjugates ,Female ,Antibodies ,Monoclonal ,Humanized ,Trastuzumab ,Receptor ,ErbB-2 ,Clinical Research ,Clinical Trials and Supportive Activities ,Colo-Rectal Cancer ,Cancer ,Digestive Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals - Abstract
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.
- Published
- 2023